Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
6.60
-0.25 (-3.65%)
At close: Aug 1, 2025, 4:00 PM
6.53
-0.07 (-1.06%)
After-hours: Aug 1, 2025, 6:49 PM EDT

Company Description

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs.

The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.

Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates.

The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.

Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics, Inc.
Mersana Therapeutics logo
CountryUnited States
Founded2001
IPO DateJun 28, 2017
IndustryBiotechnology
SectorHealthcare
Employees102
CEOMartin Huber

Contact Details

Address:
840 Memorial Drive
Cambridge, Massachusetts 02139
United States
Phone(617) 498-0020
Websitemersana.com

Stock Details

Ticker SymbolMRSN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001442836
CUSIP Number59045L106
ISIN NumberUS59045L1061
SIC Code2834

Key Executives

NamePosition
Dr. Martin H. Huber M.D.President, Chief Executive Officer and Director
Brian C. DeSchuytnerSenior Vice President, Chief Financial Officer and Chief Operating Officer
Dr. Timothy B. Lowinger Ph.D.Senior Vice President and Chief Science and Technology Officer
Alejandra Veronica Carvajal J.D.Senior Vice President, Secretary and Chief Legal Officer
Dr. Mohan Bala Ph.D.Senior Vice President and Chief Development Officer
Mikhail Papisov Ph.D.Co-Founder
Ashish MandeliaVice President and Chief Accounting Officer
Jason FredetteSenior Vice President of Investor Relations and Corporate Communications
Chuck MillerSenior Vice President of Regulatory Affairs
Dr. Marc Damelin Ph.D.Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery and Develop.

Latest SEC Filings

DateTypeTitle
Jul 24, 20258-KCurrent Report
Jul 17, 2025SCHEDULE 13G/AFiling
Jul 3, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13GFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 202510-QQuarterly Report
May 15, 20258-KCurrent Report